TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21739688

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at C4‐C7 Jiaji (EX‐B 2) for 5 min
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Reinforcing and reducing method (not specified if control or intervention)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Acupoint selection (C4‐C7 Jiaji (EX‐B 2) and others)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Time of needle retaining (5 min, 15 min)
Number of subjects: 32
Study: 19067055

Group type: EXPERIMENTAL
Intervention: Harmonic long shears (H-LS)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Regular harmonic shears (HS)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 161
Study: 16434457

Group type: COMPARATOR
Intervention: Glucose preload (1 MJ)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Protein preloads (whey, casein)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Whey preload
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lactose preload
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Casein preload
Number of subjects: 19
Study: 14688031

Group type: EXPERIMENTAL
Intervention: Ozone exposure (300 parts/billion)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fish oil (oxidants)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multivitamins (antioxidants)
Number of subjects: 16
Study: 11768323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200mg
Number of subjects: 12
Study: 9390976

Group type: EXPERIMENTAL
Intervention: High intensity exercise (80% maximal O2 uptake, n = 12)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (50% maximal O2 uptake, n = 14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Training (3 times per week for 24 weeks)
Number of subjects: 26
Study: 8355740

Group type: EXPERIMENTAL
Intervention: Ultrasound screening (2.2 sonograms per woman)
Number of subjects: 15151

Group type: COMPARATOR
Intervention: Control group (0.6 sonograms per woman)
Number of subjects: 15151

Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 15151
Study: 3396545

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with adrenaline 1:200,000 (Group 1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with adrenaline 1:200,000 (Group 2)
Number of subjects: 13
Study: 30623078

Group type: EXPERIMENTAL
Intervention: Lung function tests ('tests now' group)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Waiting list control ('waiting list' group)
Number of subjects: 674
Study: 27025240

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor letrozole (Lz; 2.5 mg/day; n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Pl; n = 14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (Lz and Pl)
Number of subjects: 30
Study: 25402401

Group type: EXPERIMENTAL
Intervention: $5, $10, or $20 for FOBT completion (Stage 1)
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: 1 in 10 chance of $50 for FOBT completion (Stage 2)
Number of subjects: 1549

Group type: COMPARATOR
Intervention: $5 fixed payment for FOBT completion (Stage 2)
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Entry into a $500 raffle for FOBT completion (Stage 2)
Number of subjects: 1549
Study: 24037226

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 798

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 798
Study: 21136235

Group type: EXPERIMENTAL
Intervention: Self-management program FIBS (six modules including information about fatigue and behavioral therapy strategies)
Number of subjects: 0
Study: 18444448

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib 40 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Rectal diclofenac 100 mg
Number of subjects: 55
Study: 22980293

Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of autologous bone-marrow derived mesenchymal stromal cells (MSCs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16444382

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (800/160 mg/day, 5 days a week)
Number of subjects: 57
Study: 12445024

Group type: EXPERIMENTAL
Intervention: Single 1 h infusion of E7070
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Daily 1 h infusion of E7070 for 5 days
Number of subjects: 75
Study: 9462603

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 2058

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2058
Study: 8534643

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate drops
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control medication
Number of subjects: 104
Study: 11527119

Group type: EXPERIMENTAL
Intervention: Bisoprolol (Bi, n = 26)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Enalapril (En, n = 30)
Number of subjects: 56
Study: 370938

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 33

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 33
Study: 12364304

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 786

Group type: COMPARATOR
Intervention: Monthly telephone contact
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Exercise therapy plus telephone contact
Number of subjects: 786

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 786
Study: 30932787

Group type: EXPERIMENTAL
Intervention: Crude palm oil fortified cookies (providing 2152 μg of β-carotene)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Crude palm oil fortified cookies
Number of subjects: 444

Group type: COMPARATOR
Intervention: Placebo cookies (non-fortified)
Number of subjects: 444
Study: 30342554

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) therapy - 16 mg per day (8 mg twice daily, days 1 to 4), halved every 3 days until 0.5 mg a day on day 19, stopped on day 20.
Number of subjects: 420

Group type: COMPARATOR
Intervention: Burr-hole craniotomy (BHC) - standard surgical intervention.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) therapy
Number of subjects: 420
Study: 26407272

Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 (3 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 (2 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 (2 or 3 doses)
Number of subjects: 0
Study: 25211490

Group type: EXPERIMENTAL
Intervention: ReLEx smile
Number of subjects: 47

Group type: COMPARATOR
Intervention: FS-LASIK
Number of subjects: 47
Study: 22378724

Group type: EXPERIMENTAL
Intervention: UNIMMAP
Number of subjects: 1294

Group type: COMPARATOR
Intervention: IFA
Number of subjects: 1294
Study: 20465648

Group type: EXPERIMENTAL
Intervention: 20mg isotretinoin, 3 times per week, nightly moisturizer, and daily sunscreen for three months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Moisturizer and sunscreen
Number of subjects: 32
Study: 18022044

Group type: EXPERIMENTAL
Intervention: Stepped-care intervention group (12 weeks of optimized antidepressant management followed by six sessions of a pain self-management program)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 500
Study: 15983242

Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg once daily)
Number of subjects: 5436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5436

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 5436
Study: 12551867

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (0.125 g/min) for 120 minutes
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion for 120 minutes
Number of subjects: 9
Study: 10778516

Group type: COMPARATOR
Intervention: High dose (2 vials over 1 hour, followed by 2 vials over 4 hours, repeated 4 hourly until clotting parameters normalized and then 2 vials as infusion over 24 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low dose (2 vials over 1 hour, followed by 1 vial over four hours, repeated 4 hourly until clotting parameters normalized and then 1 vial as infusion over 24 hours)
Number of subjects: 60
Study: 8657463

Group type: EXPERIMENTAL
Intervention: Scanning started at 80% of the contrast injection time
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Scanning started at 100% of the contrast injection time
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Scanning started at 150% of the contrast injection time
Number of subjects: 45
Study: 2050170

Group type: EXPERIMENTAL
Intervention: Clomipramine (25‐50 mg t.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25‐0.75 mg t.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6353430

Group type: EXPERIMENTAL
Intervention: 200 mg feprazone 3-times a day
Number of subjects: 200

Group type: COMPARATOR
Intervention: 200 mg feprazone twice a day
Number of subjects: 200
Study: 31486072

Group type: EXPERIMENTAL
Intervention: Self-management intervention (n = 232)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Treatment as usual or wait-list control (n = 221)
Number of subjects: 453
Study: 29786898

Group type: EXPERIMENTAL
Intervention: Modified Prolonged Exposure (mPE) therapy for PTSD
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-trauma-focused comparison treatment
Number of subjects: 126
Study: 27273910

Group type: EXPERIMENTAL
Intervention: Free lutein (10 mg daily for 3 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lutein esters (20 mg daily for 3 months, equivalent to 10 mg of free lutein)
Number of subjects: 20
Study: 24287601

Group type: EXPERIMENTAL
Intervention: Low dose of siltuximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High doses of siltuximab (predicted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free IL-6 concentration change from baseline
Number of subjects: 0
Study: 22169459

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 91
Study: 19874316

Group type: EXPERIMENTAL
Intervention: Undecylenoyl phenylalanine 2%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patient assessment ratings
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Side effects of active treatment
Number of subjects: 36
Study: 17062659

Group type: EXPERIMENTAL
Intervention: Exercise (walking, n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (low‐intensity stretching and relaxation exercises, n = 18)
Number of subjects: 38
Study: 16170758

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Decrease or no change in CD4+ cell count
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: CD4+ cell count increase ≥100-cell/mm3
Number of subjects: 228
Study: 12366423

Group type: EXPERIMENTAL
Intervention: Tacalcitol plus PUVA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tazarotene plus PUVA
Number of subjects: 31

Group type: COMPARATOR
Intervention: PUVA monotherapy
Number of subjects: 31
Study: 10544415

Group type: EXPERIMENTAL
Intervention: Relearning group (correct KR after 125 trials of erroneous KR)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Erroneous KR group
Number of subjects: 26

Group type: COMPARATOR
Intervention: No-KR group
Number of subjects: 26
Study: 7646670

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dipivefrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 80
Study: 1976738

Group type: EXPERIMENTAL
Intervention: Neurolept anaesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Enflurane/N2O
Number of subjects: 26
Study: 376030

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30267277

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation (L)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Fluoride treatment (F)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combined fluoride and laser treatment (FL)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No treatment, control (C)
Number of subjects: 240
Study: 27965285

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Tenecteplase (in patients with target mismatch)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 146
Study: 26184292

Group type: EXPERIMENTAL
Intervention: Highland barley (HB) load
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glucose (GL) load
Number of subjects: 50

Group type: COMPARATOR
Intervention: White rice (WR) load
Number of subjects: 50
Study: 24039148

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 179

Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 179
Study: 22474057

Group type: EXPERIMENTAL
Intervention: B vitamins (2 mg folic acid, 25 mg vitamin B(6), 500 μg vitamin B(12))
Number of subjects: 8164
Study: 19387377

Group type: EXPERIMENTAL
Intervention: Resistance only (R)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resistance + cycle ergometry (RC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resistance + incline treadmill (RT)
Number of subjects: 30
Study: 17599576

Group type: EXPERIMENTAL
Intervention: Expansion sphincter pharyngoplasty (ESP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Uvulopalatopharyngoplasty (Control)
Number of subjects: 45
Study: 14991555

Group type: EXPERIMENTAL
Intervention: Lactulose syrup (routine administration twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (laxative on indication)
Number of subjects: 0
Study: 12468901

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (activities in a day-care-like setting once a week for 6 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 25
Study: 9920062

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (3 or 6 microg/kg x day, s.c.) for 3 months
Number of subjects: 12
Study: 7589392

Group type: EXPERIMENTAL
Intervention: cyclosporin
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 2123791

Group type: EXPERIMENTAL
Intervention: Pravastatin 5 mg b.d. for 8 weeks followed by 10 mg b.d. for 8 weeks (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg b.d. for 8 weeks followed by 20 mg b.d. for 8 weeks (Group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 30
Study: 6171989

Group type: EXPERIMENTAL
Intervention: KWD 2131 (beta-adrenoceptor stimulant)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31288859

Group type: EXPERIMENTAL
Intervention: Mailed distribution of a direct‐to‐patient educational brochure for chronic opioid use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 28407990

Group type: EXPERIMENTAL
Intervention: New removable prosthesis insertion
Number of subjects: 30
Study: 25674699

Group type: EXPERIMENTAL
Intervention: Citrulline-Malate (CM) 8 g
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study: 23092310

Group type: EXPERIMENTAL
Intervention: Visual aids depicting multimodal treatment options for colorectal cancer
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Intensive-treatment option with clear survival benefit
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Milder treatment option without survival benefit
Number of subjects: 367

Group type: COMPARATOR
Intervention: Equally intense treatment options with different timing (neoadjuvant vs. adjuvant) without survival benefit
Number of subjects: 367
Study: 19940729

Group type: EXPERIMENTAL
Intervention: Thrust manipulation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nonthrust manipulation
Number of subjects: 112
Study: 17516768

Group type: EXPERIMENTAL
Intervention: Alcohol (0.70 g/kg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 14763496

Group type: EXPERIMENTAL
Intervention: CVVHD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CVVHpost
Number of subjects: 18

Group type: COMPARATOR
Intervention: CVVHpre
Number of subjects: 18
Study: 11228365

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) vaccine, two doses at 6 and 9 months
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) vaccine, one dose at 9 months
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Schwarz (SW) vaccine, two doses at 6 and 9 months
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Schwarz (SW) vaccine, one dose at 9 months
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) vaccine, second dose
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Schwarz (SW) vaccine, second dose
Number of subjects: 365
Study: 11689734

Group type: EXPERIMENTAL
Intervention: Elite male distance runners
Number of subjects: 25

Group type: COMPARATOR
Intervention: Male university distance runners
Number of subjects: 25

Group type: COMPARATOR
Intervention: Male untrained university students
Number of subjects: 25
Study: 9140636

Group type: EXPERIMENTAL
Intervention: Intravenous sedation (combination of haloperidol and diazepam, usually 20 mg of each)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Intravenous sedation
Number of subjects: 495
Study: 7957410

Group type: EXPERIMENTAL
Intervention: 200 micrograms inhaled oxitropium bromide (OB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 200 micrograms inhaled fenoterol (F)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 micrograms inhaled fenoterol (F)
Number of subjects: 20
Study: 3107660

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms at bedtime
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 142
Study: 1827007

Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 mg twice daily, increased to 2.5 mg if necessary)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg twice daily, increased to 25 mg if necessary)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combination of Isradipine and Captopril
Number of subjects: 140
Study: 968036

Group type: EXPERIMENTAL
Intervention: External irradiation treatment with total 1,500 rad mid-pelvic dose delivered on five consecutive days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional external irradiation technique of 5,000 rad delivered in 5 weeks
Number of subjects: 14
Study: 30826492

Group type: EXPERIMENTAL
Intervention: SSRI + vortioxetine (10–20 mg/day)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: vortioxetine (10–20 mg/day) + placebo
Number of subjects: 151

Group type: COMPARATOR
Intervention: current SSRI + placebo
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: vortioxetine (10–20 mg/day)
Number of subjects: 151
Study: 28842996

Group type: EXPERIMENTAL
Intervention: Pharyngeal packing
Number of subjects: 46

Group type: COMPARATOR
Intervention: No pharyngeal packing
Number of subjects: 46
Study: 27623234

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 24433744

Group type: EXPERIMENTAL
Intervention: Home Telehealth (HT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Care (CC)
Number of subjects: 60
Study: 22914755

Group type: EXPERIMENTAL
Intervention: Side-car bassinet
Number of subjects: 35

Group type: COMPARATOR
Intervention: Stand-alone bassinet
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 19439158

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 17489805

Group type: EXPERIMENTAL
Intervention: High-dose botulinum toxin A (BTX‐A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low-dose botulinum toxin A (BTX‐A)
Number of subjects: 39
Study: 16189994

Group type: EXPERIMENTAL
Intervention: Food purchased from a village with < 10 microg/l arsenic in irrigation water
Number of subjects: 63

Group type: COMPARATOR
Intervention: Food purchased from markets in the study village with > 100 microg/l arsenic in irrigation water
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Food from low-contamination area
Number of subjects: 63

Group type: COMPARATOR
Intervention: Food from high-contamination area
Number of subjects: 63
Study: 11914107

Group type: COMPARATOR
Intervention: alpha-tocopherol (100 mg/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: alpha-carotene + beta-carotene (15 mg/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: lutein (from marigold extracts)
Number of subjects: 400

Group type: COMPARATOR
Intervention: lycopene (from tomato paste)
Number of subjects: 400
Study: 9860093

Group type: EXPERIMENTAL
Intervention: Dual-cured resin composite luting agent
Number of subjects: 27

Group type: COMPARATOR
Intervention: Chemically cured resin composite luting agent
Number of subjects: 27
Study: 7840078

Group type: EXPERIMENTAL
Intervention: Oat extract containing 1% soluble beta-glucans
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oat extract containing 10% soluble beta-glucans
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oat extracts (1% and 10%)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oat extracts
Number of subjects: 23
Study: 2205188

Group type: EXPERIMENTAL
Intervention: 150 mg ethinyloestradiol gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: gel alone (control)
Number of subjects: 25
Study: 652210

Group type: EXPERIMENTAL
Intervention: Laminaria tents used as an adjunct to labor induction
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no laminaria)
Number of subjects: 74
Study: 31373615

Group type: EXPERIMENTAL
Intervention: Screening group (tested for anti-EBV antibodies)
Number of subjects: 70296

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 70296
Study: 28449886

Group type: EXPERIMENTAL
Intervention: Four-channel device (ApneaLink [AL], ResMed, UK) used for remote postal-based diagnostic service.
Number of subjects: 733